Dr Catherine Mummery explains more about new Alzheimer's drug lecanemab
Lecanemab is the first drug shown to slow the destruction of the brain in Alzheimer’s disease. However, NICE says there are still concerns about its effectiveness, its cost and also its safety and that for a drug that does not cure, reverse or halt Alzheimer’s disease and only slows the pace of decline, it can’t be justified.
The decision not to make it available on the NHS has caused upset and disappointment from those hoping the drug could help loved ones fight the disease.
To explain more about the drug and the decision for it to not be used on the NHS, leading Dementia specialist Catherine Mummery takes us behind the headlines.